ArticleBMC oral health2025
Comparison of level of circulating tumor DNA between oral squamous cell carcinoma and healthy controls: a case control study.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo compare circulating tumor DNA (ctDNA) levels between patients with oral squamous cell carcinoma (OSCC) and healthy controls.
methodsA case-control study was conducted at Khyber College of Dentistry and Khyber Medical University, Peshawar. A total of 124 participants (94 OSCC patients and 30 healthy controls) were recruited using a non-probability consecutive sampling technique after obtaining the written informed consent. ctDNA was extracted from plasma and quantified using Qubit fluorometry and Nanodrop spectrophotometry. Real-time polymerase chain reaction (PCR) with TaqMan probes was used for detection. Independent t-tests compared ctDNA levels between OSCC patients and controls, and linear regression was conducted to assess the influence of age, gender, tumor site, and histopathological grade on ctDNA levels.
resultsThe mean age of OSCC patients (56.82 ± 11.92 years) was significantly higher than that of controls (31.93 ± 7.10 years, p < 0.001). The most common tumor site was the buccal mucosa (20.16%), and moderately differentiated OSCC was the most prevalent histopathological grade (38.71%). The mean ctDNA level was significantly higher in OSCC cases (37.52 ± 8.71 ng/ml) compared to controls (11.00 ± 6.39 ng/ml, p < 0.001). Linear regression analysis confirmed significantly elevated ctDNA levels in OSCC cases (β = 28.13, 95% CI: 19.67–36.60, p < 0.001). Age, gender, tumor site, and histopathological grade did not significantly influence ctDNA levels.
conclusionOSCC patients exhibited significantly higher ctDNA levels than healthy controls. ctDNA quantification may serve as a promising non-invasive biomarker, though further validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.